Back
ESC2025 Premium Access

Active-target liposomal drug shows significant atherosclerotic plaque regression effect: a proof-of-concept phase 1b/2a clinical trial

Session: Atherosclerosis: prevention and new regression
Topic: Pharmacotherapy
Speaker: Professor Y. Zhou (Beijing, CN)
Event: ESC Congress 2025

Congress Presentation

Add to my library

Like

About the speaker

Professor Yu Jie Zhou

Beijing AnZhen Hospital affiliated to Capital Medical University, Beijing (China)
1 presentation
0 follower

2 more presentations in this session

State-of-the-art lecture on atherosclerotic plaque regression

Speaker: Professor L. Badimon (Barcelona, ES)

Access
Slides
Like
Thumbnail

Effect of 5-lipoxygenase-activating protein inhibiton on coronary atherosclerosis progression in patients with recent acute coronary syndrome: the PASSIVATE randomised clinical trial

Speaker: Associate Professor M. Chan (Singapore, SG)

Access
Abstract
Slides
Like
Thumbnail

Access the full session

Atherosclerosis: prevention and new regression

Speakers: Professor Y. Zhou, Professor L. Badimon, Associate Professor M. Chan
Access
Video
Like
Thumbnail

About the event

Image

ESC Congress 2025

29 August - 1 September 2025

Sessions Presentations

Congress
logo Image

ESC 365 is supported by

bristol-myers-squibb Explore sponsored resources
novartis Explore sponsored resources